Back to Search
Start Over
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
- Publication Year :
- 2022
- Publisher :
- BMJ Publishing Group, 2022.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 10
- Issue :
- 4
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.b2e4c24b8fb47d8a3db8e4d8d7b86fe
- Document Type :
- article
- Full Text :
- https://doi.org/10.1136/jitc-2022-004656